Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL

Publish date:: June 28, 2019

Key clinical point: Durvalumab plus R-CHOP produced complete responses in patients with previously untreated, high-risk diffuse large B-cell lymphoma (DLBCL).

Major finding: Durvalumab plus R-CHOP induction produced a complete response rate of 54%.

Study details: A phase 2 trial of 43 patients with previously untreated, high-risk DLBCL.

Disclosures: The trial was sponsored by Celgene. Researchers reported relationships with Celgene and other companies.

Citation:

Nowakowski GS et al. ASCO 2019, Abstract 7520.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,